DYNAMIC CHANGE IN PLASMA EGFR MUTATION DNA IN RESPONSE TO FIRST LINE THERAPY FOR ADVANCED STAGE NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Mok, Tony [1 ]
Wu, Yi-Long [2 ]
Lee, Jin Soo [3 ]
Yu, Chong-Jen [4 ]
Sriuanpong, Virotw [5 ,6 ]
Wen, Wei [7 ]
Tsai, Julie [7 ]
Trueman, Matt [8 ]
Klughammer, Barbara [9 ]
Wu, Lin [7 ]
机构：
[1] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China
[2] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Peoples R China
[3] Natl Canc Ctr, Res Inst & Hosp, Lung Canc Branch, Singapore, Singapore
[4] Natl Taiwan Univ Hosp, Zhongzheng, Taiwan
[5] King Chulalongkorn Mem Hosp, Bangkok, Thailand
[6] Chulalongkorn Univ, Bangkok 10330, Thailand
[7] Roche Mol Syst Inc, Genom & Onocl Dept Res, Pleasanton, CA USA
[8] Roche Prod Ltd, Melbourne, Vic, Australia
[9] Hoffmann la Roche Ltd, Basel, Switzerland
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
EGFR; mutation; plasma DNA; allele-specific PCR;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O01.06
引用
收藏
页码：S133 / S134
页数：2
相关论文
共 50 条
  • [1] EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
    Fong, Thomas
    Morgensztern, Daniel
    Govindan, Ramaswamy
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (03) : 303 - 310
  • [2] Plasma EGFR mutation abundance affects clinical response to first-line EGFR-TKIs in patients with advanced non-small cell lung cancer
    Wang, Xiaohong
    Liu, Yonggang
    Meng, Zhiying
    Wu, Yun
    Wang, Shubin
    Jin, Gaowa
    Qin, Yingchun
    Wang, Fengyun
    Wang, Jing
    Zhou, Haifei
    Su, Xiaoxing
    Fu, Xiuhua
    Wang, Xiaolan
    Shi, Xiaoyu
    Wen, Zhenping
    Jia, Xiaoqiong
    Qin, Qiong
    Gao, Yongqiang
    Guo, Weidong
    Lu, Shun
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (08)
  • [3] Docetaxel (Taxotere®) as first-line therapy of advanced non-small cell lung cancer (NSCLC)
    Manegold, C
    ONKOLOGIE, 2003, 26 : 26 - 32
  • [4] First-line treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) by gefitinib
    Moiseyenko, V.
    Procenko, S. A.
    Levchenko, E. V.
    Barchuk, A. S.
    Matsko, D. E.
    Moiseyenko, F. V.
    Ivantsov, A. O.
    Iyevleva, A. G.
    Mitiushkina, N. V.
    Imyanitov, E. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] Third Line Therapy in EGFR Positive Advanced Non-Small Cell Lung Cancer
    Pande, Nikhil
    Joshi, Amit
    Noronha, Vanita
    Patil, Vijay
    Chougule, Anuradha
    Janu, Amit
    More, Sucheta
    Goud, Supriya
    Karpe, Ashay
    Ramaswamy, Anant
    Chandrasekharan, Arun
    Talreja, Vikas
    Goel, Alok
    Prabhash, Kumar
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1229 - S1230
  • [6] EGFR mutation in non-small cell lung cancer(NSCLC) in South Croatia
    Mladinov, Suzana
    Skopljanac, Ivan
    Ivcevic, Veljka
    Kuret, Sendi
    Durdov, Meri Glavina
    Mise, Kornelija
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [7] Efficacy and safety study of osimertinib in advanced non-small cell lung cancer (NSCLC) with EGFR mutation
    Garcia Samblas, Victoria
    Fernandez Madrigal, Laura
    Rodriguez Garces, Maria Yeray
    Inoriza, Angel
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] EGFR mutation and management of advanced non-small cell lung cancer (NSCLC) adenocarcinoma in Germany and France
    Souquet, P. J.
    Dietel, M.
    Eberhardt, W.
    Fournel, P.
    Von der Schulenburg, J. M. Graf
    Locher, C.
    Sabourin, J. C.
    Schirmacher, P.
    Thomas, M.
    Schuette, W.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S817 - S817
  • [9] COST-EFFECTIVENESS OF FIRST-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Yang, M. C.
    Tan, E. C. H.
    VALUE IN HEALTH, 2014, 17 (07) : A736 - A736
  • [10] Evaluation of EGFR mutation testing in plasma from non-small cell lung cancer (NSCLC) patients
    Gonzalez De Aledo-Castillo, J. M.
    Victoria, I.
    Arcocha, A.
    Reguart, N.
    Molina Porto, R.
    Puig-Butille, J. A.
    CLINICA CHIMICA ACTA, 2019, 493 : S570 - S570
12345